Tango Therapeutics
TNGX
126 hedge funds and large institutions have $781M invested in Tango Therapeutics in 2024 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 35 increasing their positions, 41 reducing their positions, and 16 closing their positions.
46% more call options, than puts
Call options by funds: $19K | Put options by funds: $13K
38% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 16
4% more funds holding
Funds holding: 121 → 126 (+5)
0.24% more ownership
Funds ownership: 91.96% → 92.2% (+0.24%)
15% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 41
16% less capital invested
Capital invested by funds: $929M → $781M (-$147M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$43.2M |
| 2 |
AG
Artal Group
Luxembourg
|
+$23.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$20.2M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$5.39M |
| 5 |
MGB
Mass General Brigham
Somerville,
Massachusetts
|
+$3.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$19.5M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$11.9M |
| 3 |
PA
Perceptive Advisors
New York
|
-$11M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$4.71M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.17M |
TNGX Hedge Fund Activity: Q1 2024 in Review
126 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q1 2024, worth a combined $781M — down 16% from $929M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new TNGX positions and 16 closed out — a net gain of 6 holders — while 35 added to existing stakes and 41 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $43.2M. The largest seller was RTW Investments, exiting entirely with an estimated $19.5M sold.
- 126 institutional investors held Tango Therapeutics (TNGX) as of Q1 2024, up from 121 in Q4 2023.
- Funds reported $781M of Tango Therapeutics stock for Q1 2024, down 16% quarter-over-quarter.
- 22 funds opened new Tango Therapeutics positions in Q1 2024 and 16 closed out, a net change of +6 holders.
- The largest Tango Therapeutics buyer in Q1 2024 was T. Rowe Price Investment Management, an estimated $43.2M added.
- The largest Tango Therapeutics seller in Q1 2024 was RTW Investments, an estimated $19.5M sold.
Based on aggregated 13F filings for Q1 2024.